Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-24-052575
Filing Date
2024-12-30
Accepted
2024-12-30 20:03:01
Documents
1
Period of Report
2024-12-23

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 4064
  Complete submission text file 0001493152-24-052575.txt   5549
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Issuer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY UT 84108
Business Address
Fogarty Krista (Reporting) CIK: 0001906986 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36357 | Film No.: 241590943